MARK2 and Hyperglycemia: Under insulin-resistant states, insulin response is impaired in liver, skeletal muscle, white adipose tissue, the vasculature, and the kidney leading to hyperglycemia, hyperinsulinemia, high plasma free fatty acid levels, and inflammation-activated serine/threonine kinases.